Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2−) breast cancer patients in the United States: 2002–2012
- 14 April 2014
- journal article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 30 (8), 1537-1545
- https://doi.org/10.1185/03007995.2014.908829
Abstract
Clinical guidelines recommend that patients with HR+/HER2- metastatic breast cancer (mBC), the most prevalent mBC subtype, receive three lines of endocrine therapy (ET) prior to transitioning to chemotherapy (CT) in the absence of need for rapid response, symptomatic visceral disease, or suspected endocrine resistance. Little is known about real-world ET treatment patterns among HR+/HER2- mBC patients. Post-menopausal women with HR+/HER2- mBC were identified in the MarketScan databases (2002Q3-2012Q2). Patients were classified as receiving either ET or CT as their first therapy post-mBC diagnosis. Those receiving ET were studied further and stratified into three subgroups based on which of the following events occurred first: transition to CT, discontinuation of ET (90 days without evidence of ET), or end of data or insurance eligibility. Mean numbers of lines of ET and median durations of each line were summarized for the overall sample and subgroups. Among a total of 19,120 HR+/HER2- mBC patients, 11,545 (60%) initiated an ET; median follow-up time for these patients was 17 months. Seventy-four percent did not receive a second ET. The average patient received 1.36 lines of ET. Among patients with 2+ lines of ET, the duration of each subsequent line was significantly shorter than the previous line. RESULTS were similar in all subgroups. Clinical characteristics and reasons for treatment choices are unavailable in claims data. Fewer than two thirds of patients initiated treatment for HR+/HER2- mBC with ET. Among those who did, most received only one line of ET before discontinuation or transition to CT. Patients who received multiple lines of ET experienced shorter durations of therapy with each line. Real-world treatment with ET falls short of the targets recommended by guidelines, representing unmet need for treatment options that improve the effectiveness of endocrine therapy.Keywords
This publication has 22 references indexed in Scilit:
- Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysisBreast Cancer Research and Treatment, 2013
- Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals Of Oncology, 2012
- 1st International consensus guidelines for advanced breast cancer (ABC 1)The Breast, 2012
- Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer PatientsJournal of Clinical Oncology, 2010
- The epidemiology of triple-negative breast cancer, including raceCancer Causes & Control, 2009
- Overview of Resistance to Systemic Therapy in Patients with Breast CancerAdvances in Experimental Medicine and Biology, 2007
- Goals of Treatment for Patients With Metastatic Breast CancerSeminars in Oncology, 2006
- Goals and Objectives in the Management of Metastatic Breast CancerThe Oncologist, 2003
- Impact of Nausea and Vomiting on Quality of Life in Cancer Patients During ChemotherapyHealth and Quality of Life Outcomes, 2003
- Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast CancerJNCI Monographs, 2001